Lates News

AbbVie announced on June 4th that the National Medical Products Administration (NMPA) of China has approved Ruxolitinib (15mg once daily) for the treatment of adult patients with giant cell arteritis (GCA). This approval comes just over a month after its approval in the United States and European Union, making Ruxolitinib the first and only oral JAK inhibitor approved for the treatment of GCA in adult patients in China.